Dernières nouvelles

Information non disponible

Kim DDH, Popradi G, Lepic K, Paulson K, Allan D, Nampoothiri RV, Lachance S, Deotare U, White J, Elemary M, Jamani K, Fraga C, Lemieux C, Novitzky-Basso I, Law AD, Kumar R, Walker I, Schultz KR,

Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development

Article de revue

Curr Oncol, 31 (3), 2024.

Résumé | Liens:

Murray A, Linn SM, Yu B, Novitzky-Basso I, Mattsson J, Kennah M, Elemary M, White J, Lemieux C, Jamani K, Kim DDH

Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease

Article de revue

Bone Marrow Transplant, 2024.

Résumé | Liens:

Audet S, Doyle C, Lemieux C, Tardif MA, Gauvreau A, Simonyan D, Nabi H, Lemieux J

Adherence to CONSORT Guidelines and Reporting of the Determinants of External Validity in Clinical Oncology Randomized Controlled Trials: A Review of Trials Published in Four Major Journals between 2013 and 2015

Article de revue

Curr Oncol, 30 (2), 2023.

Résumé | Liens:

Benoit A, B Boies MH, Déry N, M Garcia L, Simard M, Poirier M, Delage R, Lortal Canguilhem B, Doyle C, Larouche JF, Couture F, Lemieux C

CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study

Article de revue

Clin Lymphoma Myeloma Leuk, 23 (3), 2023.

Résumé | Liens:

Ball G, Lemieux C, Cameron D, Seftel MD

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada

Article de revue

Curr Oncol, 29 (3), 2022.

Résumé | Liens:

Signaler des ajouts ou des modifications